Back to Search Start Over

Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment

Authors :
Rosamilio R
Valentina Giudice
Ferrara I
Annunziata S
Pezzullo L
Villani G
Baldi C
Guariglia R
Rocco M
Selleri C
Source :
Europe PubMed Central, Translational Medicine @ UniSa
Publication Year :
2016
Publisher :
Universita' degli Studi di Salerno, 2016.

Abstract

T-large granular lymphocyte leukemia (T-LGLL) is a chronic clonal proliferation of effector memory cytotoxic CD3+CD57+CD56− T cells and the current guidelines suggest immunosuppressive therapy as first-line therapy, but the treatment of refractory/relapsed patients is still challenging due to the lack of prospective studies. We describe a series of two refractory/relapsed T-LGLL patients successfully treated with bendamustine, a chemotherapeutic agent largely used for B-cell neoplasms, but poorly investigated for the treatment of T-cell diseases. Complete remission (CR) was achieved in 3 and 6 months, respectively, and maintained for at least 20 months. One patient relapsed after a 20-month CR, but she was responsive to bendamustine therapy again, obtaining a further prolonged CR. Bendamustine as single agent or in combination could be a feasible therapeutic option in refractory/relapsed T-LGLL, especially for elderly patients because of its safety profile.

Details

Database :
OpenAIRE
Journal :
Europe PubMed Central, Translational Medicine @ UniSa
Accession number :
edsair.doi.dedup.....47e008f5a4f08cec77e9e581ac887e73
Full Text :
https://doi.org/10.14273/unisa-2671